Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 6/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 8/20 | 0.39 |
| ▸ | CAMK1D | Q8IU85 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30751528 | 0.90 | SYK (0.49) | SYKCAMK1DJAK2JAK1 | |
| SCHEMBL30751486 | 0.89 | GPR119 (0.46) | PDE10AJAK2JAK1 | |
| SCHEMBL30751545 | 0.89 | GPR119 (0.46) | PDE10AJAK2JAK1 | |
| SCHEMBL30751509 | 0.83 | SYK (0.46) | SYKPDE10ACAMK1DALK | |
| Hydrochloric Acid SCHEMBL30751551 | 0.83 | ROCK2 (0.46) | PDE10ACAMK1DJAK2JAK1 | |
| Hydrochloric Acid SCHEMBL30751542 | 0.83 | ROCK2 (0.46) | PDE10ACAMK1DJAK2JAK1 | |
| SCHEMBL31673014 | 0.81 | STK17A (0.46) | CAMK1DJAK2JAK1 | |
| Hydrochloric Acid SCHEMBL31673031 | 0.80 | STK17A (0.46) | CAMK1DJAK2JAK1 | |
| SCHEMBL30751499 | 0.79 | GPR119 (0.46) | SYKCAMK1DJAK2JAK1 | |
| SCHEMBL30751518 | 0.79 | MAPT (0.44) | SYKJAK2JAK1METALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257051-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AS TYK2 INHIBITORS | 1910 GENETICS INC (US) | 2025-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257051-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AS TYK2 INHIBITORS | TYK2, PDXK, JAK1 | SYK 201/4885PDE10A 4165/4885CAMK1D 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.